CN116327897A - 用于心血管病况的利拉鲁肽 - Google Patents

用于心血管病况的利拉鲁肽 Download PDF

Info

Publication number
CN116327897A
CN116327897A CN202310320736.6A CN202310320736A CN116327897A CN 116327897 A CN116327897 A CN 116327897A CN 202310320736 A CN202310320736 A CN 202310320736A CN 116327897 A CN116327897 A CN 116327897A
Authority
CN
China
Prior art keywords
subject
liraglutide
placebo
compared
mace
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN202310320736.6A
Other languages
English (en)
Chinese (zh)
Inventor
S.拉斯姆森
K.卡维斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59723004&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN116327897(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CN116327897A publication Critical patent/CN116327897A/zh
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
CN202310320736.6A 2016-03-04 2017-03-03 用于心血管病况的利拉鲁肽 Withdrawn CN116327897A (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
EP16158739 2016-03-04
EP16158739.9 2016-03-04
EP16173917.2 2016-06-10
EP16173917 2016-06-10
EP16001329.8 2016-06-13
EP16001329 2016-06-13
US15/401,651 US9968659B2 (en) 2016-03-04 2017-01-09 Liraglutide in cardiovascular conditions
US15/401651 2017-01-09
PCT/EP2017/054990 WO2017149112A1 (en) 2016-03-04 2017-03-03 Liraglutide in cardiovascular conditions
CN201780015266.5A CN108778317A (zh) 2016-03-04 2017-03-03 用于心血管病况的利拉鲁肽

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780015266.5A Division CN108778317A (zh) 2016-03-04 2017-03-03 用于心血管病况的利拉鲁肽

Publications (1)

Publication Number Publication Date
CN116327897A true CN116327897A (zh) 2023-06-27

Family

ID=59723004

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310320736.6A Withdrawn CN116327897A (zh) 2016-03-04 2017-03-03 用于心血管病况的利拉鲁肽
CN201780015266.5A Pending CN108778317A (zh) 2016-03-04 2017-03-03 用于心血管病况的利拉鲁肽

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780015266.5A Pending CN108778317A (zh) 2016-03-04 2017-03-03 用于心血管病况的利拉鲁肽

Country Status (24)

Country Link
US (2) US9968659B2 (https=)
EP (1) EP3423082B1 (https=)
JP (1) JP6940512B2 (https=)
KR (1) KR102417455B1 (https=)
CN (2) CN116327897A (https=)
AU (2) AU2017225841A1 (https=)
BR (1) BR112018067344A2 (https=)
CA (1) CA3013532C (https=)
CL (1) CL2018002515A1 (https=)
DK (1) DK3423082T5 (https=)
ES (1) ES2893755T3 (https=)
HR (1) HRP20211492T1 (https=)
HU (1) HUE055844T2 (https=)
IL (1) IL261169B (https=)
MA (1) MA43704A (https=)
MX (1) MX394179B (https=)
MY (1) MY195657A (https=)
PH (1) PH12018501844B1 (https=)
PL (1) PL3423082T3 (https=)
RS (1) RS62501B1 (https=)
RU (1) RU2745604C2 (https=)
SI (1) SI3423082T1 (https=)
WO (1) WO2017149112A1 (https=)
ZA (1) ZA201805538B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9968659B2 (en) 2016-03-04 2018-05-15 Novo Nordisk A/S Liraglutide in cardiovascular conditions
CA3022535A1 (en) 2016-04-28 2017-11-02 Novo Nordisk A/S Semaglutide in cardiovascular conditions
CA3177693A1 (en) 2019-04-05 2020-10-05 Eli Lilly And Company Therapeutic uses of dulaglutide
US20240050531A1 (en) * 2020-12-16 2024-02-15 The Chinese University Of Hong Kong A method for reversing aging brain functional decline

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5808203A (en) 1997-05-12 1998-09-15 Medrad, Inc. Fluid pressure measurement devices
WO2003084563A1 (en) 2002-04-04 2003-10-16 Novo Nordisk A/S Glp-1 agonist and cardiovascular complications
DK3300721T4 (da) * 2003-11-20 2025-03-03 Novo Nordisk As Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
CN101056650A (zh) * 2004-11-12 2007-10-17 诺和诺德公司 促胰岛素肽的稳定制剂
EP2190872B1 (en) * 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AR075204A1 (es) 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
MX2011009852A (es) 2009-03-27 2011-09-29 Bristol Myers Squibb Co Metodos para prevenir episodios cardiovasculares adversos mayores con inhibidores de dipeptidil peptidasa iv.
US8691763B2 (en) 2010-05-04 2014-04-08 Glaxosmithkline Llc Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
WO2011161161A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US20130172244A1 (en) * 2011-12-29 2013-07-04 Thomas Klein Subcutaneous therapeutic use of dpp-4 inhibitor
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
JP6374862B2 (ja) 2012-05-24 2018-08-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 自己免疫性糖尿病、特に、ｌａｄａの治療に使用するためのｄｐｐ−４阻害剤としてのキサンチン誘導体
CN103893744B (zh) * 2012-12-24 2017-12-19 杭州九源基因工程有限公司 一种治疗糖尿病的药物制剂及其制备方法
EP3744327A1 (en) 2013-03-15 2020-12-02 Boehringer Ingelheim International GmbH Use of linagliptin in cardio- and renoprotective antidiabetic therapy
EP3007701A1 (en) 2013-06-14 2016-04-20 Boehringer Ingelheim International GmbH Dpp-4 inhibitors for treating diabetes and its complications
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
WO2016019587A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [7, 6]-fused bicyclic antidiabetic compounds
US9968659B2 (en) 2016-03-04 2018-05-15 Novo Nordisk A/S Liraglutide in cardiovascular conditions

Also Published As

Publication number Publication date
RU2745604C2 (ru) 2021-03-29
KR102417455B1 (ko) 2022-07-06
IL261169A (en) 2018-10-31
RU2018134061A (ru) 2020-04-06
DK3423082T3 (da) 2021-10-11
US9968659B2 (en) 2018-05-15
SI3423082T1 (sl) 2021-10-29
JP2019507174A (ja) 2019-03-14
PL3423082T3 (pl) 2021-12-27
RU2018134061A3 (https=) 2020-07-15
MX2018010097A (es) 2018-11-09
US20170252408A1 (en) 2017-09-07
EP3423082B1 (en) 2021-08-04
HUE055844T2 (hu) 2021-12-28
WO2017149112A1 (en) 2017-09-08
MA43704A (fr) 2021-04-14
ES2893755T3 (es) 2022-02-10
CL2018002515A1 (es) 2018-11-09
PH12018501844A1 (en) 2019-05-15
IL261169B (en) 2019-11-28
CA3013532C (en) 2019-07-23
CN108778317A (zh) 2018-11-09
ZA201805538B (en) 2020-05-27
EP3423082A1 (en) 2019-01-09
AU2024201937A1 (en) 2024-04-11
CA3013532A1 (en) 2017-09-08
DK3423082T5 (da) 2023-02-06
AU2017225841A1 (en) 2018-08-23
US20180236038A1 (en) 2018-08-23
KR20180114168A (ko) 2018-10-17
HRP20211492T1 (hr) 2021-12-24
MX394179B (es) 2025-03-24
PH12018501844B1 (en) 2023-03-17
JP6940512B2 (ja) 2021-09-29
RS62501B1 (sr) 2021-11-30
BR112018067344A2 (pt) 2019-01-08
MY195657A (en) 2023-02-03

Similar Documents

Publication Publication Date Title
RU2768283C2 (ru) Семаглутид при сердечно-сосудистых состояниях
AU2024201937A1 (en) Liraglutide in cardiovascular conditions
CN110022935A (zh) 用于心血管病况的德谷胰岛素
US20200181222A1 (en) Insulin degludec for improvement of glycaemic control and reduction of acute and long-term diabetes complications
US20190091295A1 (en) Liraglutide in Renal Conditions
WO2017149109A1 (en) Liraglutide in diabetic foot ulcer
HK1259166B (en) Liraglutide in cardiovascular conditions
HK1259166A1 (en) Liraglutide in cardiovascular conditions
HK1261741A1 (en) Semaglutide in cardiovascular conditions
HK1261741B (en) Semaglutide in cardiovascular conditions

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20230627

WW01 Invention patent application withdrawn after publication